We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
9
Feb 2026
A long-standing Medicare policy meant to manage rehabilitation services in nursing homes may keep older Americans in hospitals longer than necessary without improving patient health or saving Medicare money, new research finds.
9
Feb 2026
A new study from McMaster University involving 2.8 million children around the world has revealed the most important early-life factors that influence whether a child becomes allergic to food.
9
Feb 2026
Pancreatic cancer has a lot of nerve. Notoriously tricky to detect, the disease also often resists traditional therapy. So, researchers are urgently looking for new ways to disrupt tumor formation.
9
Feb 2026
A new randomized controlled study funded by the Crohn's & Colitis Foundation found that time-restricted feeding-a form of intermittent fasting-significantly reduced symptomatic disease activity and systematic inflammation in adults with Crohn's disease and overweight or obesity.